lonapegsomatropin · Skytrofa
Protein / enzyme therapeutic
Evidence outlook
Approved: Growth Hormone Deficiency
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- Pediatric growth hormone deficiency (by VISEN, Chinese brand LongPei)
- Growth failure in children and adolescents aged 3 to 18 years due to growth hormone deficiency
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
foresiGHt NCT04615273 · Growth Hormone Deficiency This randomized Phase 3 trial assigned 264 adults with growth hormone deficiency to once-weekly lonapegsomatropin, matching placebo or open-label daily somatropin; the lonapegsomatropin and placebo arms were double-blind and formed the primary comparison. The primary endpoint, change in trunk percent fat measured by DXA at Week 38, was met: trunk fat fell by 1.68 percentage points on lonapegsomatropin and rose by 0.37 on placebo (difference -2.04, 95% CI -2.94 to -1.14, p<0.0001). The record reports no power calculation or planned enrolment. Registry: NCT04615273 | 3 | Change From Baseline in Trunk Percent Fat at Week 38 (Baseline, Week 38) 2023-11-02 | Change From Baseline in Trunk Percent Fat at Week 38 (Baseline, Week 38): Lonapegsomatropin -1.68 percent fat (95% CI -2.44 to -0.91) | Placebo 0.37 percent fat (95% CI -0.3 to 1.03) | Partial signal | link ↗ |
View 2 more trials
NCT05171855 NCT05171855 · Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency This was a genuine open-label extension of the randomized TCH-306 trial, with 220 participants continuing from that study, but treatment in the extension was nonrandomized and unblinded and there was no concurrent control arm. The primary endpoint was descriptive safety reporting rather than a formal efficacy comparison, so the findings provide useful longer-term extension evidence but limited comparative evidence. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAE Leading to Study Discontinuation". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT05171855 | 3 | Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAE Leading to Study Discontinuation (Up to 52 Weeks) 2024-12-23 | Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAE Leading to Study Discontinuation (Up to 52 Weeks): Lonapegsomatropin/Lonapegsomatropin — TEAEs: 48 Participants; Serious TEAEs: 7 Participants; TEAE Leading to Study Discontinuation: 2 Participants | Placebo/Lonapegsomatropin — TEAEs: 52 Participants; Serious TEAEs: 4 Participants; TEAE Leading to Study Discontinuation: 4 Participants | Somatropin/Lonapegsomatropin — TEAEs: 45 Participants; Serious TEAEs: 5 Participants; TEAE Leading to Study Discontinuation: 2 Participants | Weak signal | link ↗ |
NCT02781727 NCT02781727 · Growth Hormone Deficiency Registry: NCT02781727 | 3 | Annualized Height Velocity at 52 Weeks for Weekly Lonapegsomatropin and Daily hGH Treatment Groups 2019-01-17 | Annualized Height Velocity at 52 Weeks for Weekly Lonapegsomatropin and Daily hGH Treatment Groups (52 weeks): Lonapegsomatropin 11.17 cm/year (Standard Error 0.23) | Daily hGH 10.31 cm/year (Standard Error 0.3) | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other Growth hormone receptor drugs
somatrogon, Somatropin, Somatropin (Jintropin). Compare all 4 Growth hormone receptor drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Growth Hormone Deficiency: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Lonapegsomatropin (Skytrofa): this drug | Approved | Protein / enzyme therapeutic | Growth hormone receptor | Partial signal | Featured results are safety and non-efficacy only in this race | |
| Somatrogon (NGENLA) | Approved | Protein / enzyme therapeutic | Growth hormone receptor | Partial signal | NCT03831880: Overall life interference total score (DCOA 1), crossover: weekly somatrogon 8.63 vs daily Genotropin 24.13; difference -15.49 (95% CI -19.71 to -11.27), p<0.0001 (CT.gov posted results). | |
| Somatropin (Serostim) | Approved(overall) | Protein / enzyme therapeutic | Growth hormone receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Somatropin (Jintropin) | Phase 3(overall) | Biologic (subtype unspecified) | Growth hormone receptor | Partial signal(overall) | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Skytrofa (lonapegsomatropin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.